- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
A-769662是一種有效的,可逆的AMPK激活劑,在無細胞試驗中EC50為0.8 μM,對GPPase/FBPase活性幾乎沒有作用。
A-769662 Chemical Structure
CAS: 844499-71-4
相關(guān)產(chǎn)品 | Dorsomorphin 2HCl Dorsomorphin AICAR (Acadesine) GSK621 WZ4003 ex229 (compound 991) Phenformin HCl HTH-01-015 BAY-3827 O-304 MK-3903 BAM 15 Danthron | 點擊展開 |
---|---|---|
相關(guān)化合物庫 | 激酶抑制劑庫 PI3K/Akt 抑制劑庫 凋亡分子化合物庫 細胞周期化合物庫 NF-κB信號通路庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
HeLa | Function assay | 100 uM | 1 hr | Effect on AMPK activation in HeLa cells at 100 uM after 1 hr by immunoprecipitate kinase assay | 17855357 |
HeLa | Function assay | 100 uM | 1 hr | Effect on AMPK phosphorylation in HeLa cells at 100 uM after 1 hr by immunoprecipitate kinase assay | 17855357 |
HeLa | Function assay | 100 uM | 5 mins | Effect on AMPK phosphorylation in HeLa cells at 100 uM after 5 mins by immunoprecipitate kinase assay | 17855357 |
HeLa | Function assay | 100 uM | 1 hr | Effect on acetyl-CoA carboxylase phosphorylation in HeLa cells at 100 uM after 1 hr by densitometry | 17855357 |
HeLa | Function assay | 100 uM | 1 hr | Reduction of AMPK phosphorylation in HeLa cells at 100 uM after 1 hr in presence of STO-609 by immunoprecipitate kinase assay | 17855357 |
HeLa | Function assay | 100 uM | 1 hr | Reduction of AMPK activation in HeLa cells at 100 uM after 1 hr in presence of STO-609 by immunoprecipitate kinase assay | 17855357 |
HeLa | Function assay | 100 uM | 1 hr | Reduction of acetyl-CoA carboxylase phosphorylation in HeLa cells at 100 uM after 1 hr in presence of STO-609 by densitometry | 17855357 |
MG-63 | cytotoxicity assay | 10 μM | inhibits H2O2-Induced Osteoblast Cell Death | 24960362 | |
Mesenchymal stem cells | cytotoxicity assay | 100 μM | decreases the MSC proliferation | 24104879 | |
Mesenchymal stem cells | Kinase assay | 10 μM | induces a robust and sustained AMPK activation | 24104879 | |
MCF7 | Apoptosis assay | 400 μM | sensitizes human breast cancer cell lines to TRAIL-induced apoptosis | 19896469 | |
BT474 | Apoptosis assay | 400 μM | sensitizes human breast cancer cell lines to TRAIL-induced apoptosis | 19896469 | |
MDA-MB231 | Apoptosis assay | 400 μM | sensitizes human breast cancer cell lines to TRAIL-induced apoptosis | 19896469 | |
L6 skeletal muscle cells | Function assay | 250 μM | inhibits the Na+-K+-ATPase transport activity and cell surface abundance | 19828836 | |
L6 skeletal muscle cells | Function assay | 250 μM | activates AMPK signaling pathways | 19828836 | |
3T3-L1 | Kinase assay | 1.2 mM | activates AMPK | 19483304 | |
3T3-L1 | cytotoxicity assay | 1.2 mM | decreases Cell Viability | 19483304 | |
3T3-L1 | Function assay | 1.2 mM | inhibits Mitotic Clonal Expansion | 19483304 | |
3T3-L1 | Function assay | 1.2 mM | inhibits the Expression of AdipogenesisRelated Transcription Factors and Markers | 19483304 | |
3T3-L1 | Function assay | 1.2 mM | inhibits 3T3-L1 Adipogenesis | 19483304 | |
epididymal clear cells | Function assay | 200 μM | inhibits the pH-mediated V-ATPase accumulation at the apical membrane | 19211918 | |
MEFs | Function assay | 300 μM | inhibits proteasomal function by an AMPK-independent mechanism | 18593584 | |
CCL13 | Kinase assay | 200 μM | activates endogenous AMPK | 17728241 | |
HEK293 | Kinase assay | 200 μM | activates endogenous AMPK | 17728241 | |
rat hepatocytes | Function assay | 1 mM | inhibits fatty acid synthesis with IC50 of 3.6 μM | 16753576 | |
mouse hepatocytes | Function assay | 1 mM | inhibits fatty acid synthesis with IC50 of 3.6 μM | 16753576 | |
MC3T3-E1 | cytotoxicity assay | 10 μM | inhibits H2O2-Induced Osteoblast Cell Death | 24960362 | |
MG-63 | Apoptosis assay | 10 μM | suppresses H2O2-Induced Osteoblast Cell Apoptosis | 24960362 | |
MC3T3-E1 | Apoptosis assay | 10 μM | suppresses H2O2-Induced Osteoblast Cell Apoptosis | 24960362 | |
MG-63 | Function assay | 10 μM | alleviates ROS accumulation and ATP depletion caused by H2O2 | 24960362 | |
MC3T3-E1 | Function assay | 10 μM | alleviates ROS accumulation and ATP depletion caused by H2O2 | 24960362 | |
MG-63 | Function assay | 10 μM | facilitates H2O2-induced autophagy activation | 24960362 | |
MC3T3-E1 | Function assay | 10 μM | facilitates H2O2-induced autophagy activation | 24960362 | |
PC3 | Kinase assay | 100 μM | upregulates the levels of AMPK and ACC phosphorylation | 25594043 | |
PC3M | Kinase assay | 100 μM | upregulates the levels of AMPK and ACC phosphorylation | 25594043 | |
PC3 | Function assay | 100 μM | induces PI3K/mTOR pathways | 25594043 | |
PC3M | Function assay | 100 μM | induces PI3K/mTOR pathways | 25594043 | |
PC3 | Growth inhibitory assay | 100 μM | suppresses proliferation | 25594043 | |
PC3M | Growth inhibitory assay | 100 μM | suppresses proliferation | 25594043 | |
MC3T3-E1 | Kinase assay | 10 μM | induces significant AMPK activation | 26891866 | |
MC3T3-E1 | Growth inhibitory assay | 10 μM | inhibits Dex-induced osteoblast cell death | 26891866 | |
MC3T3-E1 | Function assay | 10 μM | inhibits Dex-induced oxidative stress | 26891866 | |
BL21 | Function assay | 1 to 10 mins | Binding affinity to human recombinant N-terminal AVI-tagged phosphorylated AMPK alpha1beta1gamma1 expressed in Escherichia coli BL21 cells after 1 to 10 mins by biolayer interferometry, Kd = 0.51 μM. | 26510622 | |
BL21 | Function assay | 1 to 10 mins | Binding affinity to human recombinant N-terminal AVI-tagged phosphorylated AMPK alpha1beta2gamma1 expressed in Escherichia coli BL21 cells after 1 to 10 mins by biolayer interferometry, Kd = 14.5 μM. | 26510622 | |
CMK | Growth Inhibition Assay | Inhibition of human CMK cell growth in a cell viability assay, IC50 = 0.002202 μM. | SANGER | ||
SIG-M5 | Growth Inhibition Assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50 = 0.007856 μM. | SANGER | ||
MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.02274 μM. | SANGER | ||
GDM-1 | Growth Inhibition Assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50 = 0.02553 μM. | SANGER | ||
A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 0.02919 μM. | SANGER | ||
NALM-6 | Growth Inhibition Assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50 = 0.03166 μM. | SANGER | ||
KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.03213 μM. | SANGER | ||
QIMR-WIL | Growth Inhibition Assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 0.03642 μM. | SANGER | ||
NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 0.03689 μM. | SANGER | ||
KASUMI-1 | Growth Inhibition Assay | Inhibition of human KASUMI-1 cell growth in a cell viability assay, IC50 = 0.0418 μM. | SANGER | ||
ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.04344 μM. | SANGER | ||
YT | Growth Inhibition Assay | Inhibition of human YT cell growth in a cell viability assay, IC50 = 0.0467 μM. | SANGER | ||
Daudi | Growth Inhibition Assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50 = 0.04979 μM. | SANGER | ||
OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 0.0572 μM. | SANGER | ||
ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 0.05793 μM. | SANGER | ||
MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 0.06191 μM. | SANGER | ||
EHEB | Growth Inhibition Assay | Inhibition of human EHEB cell growth in a cell viability assay, IC50 = 0.06325 μM. | SANGER | ||
AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 0.0644 μM. | SANGER | ||
C8166 | Growth Inhibition Assay | Inhibition of human C8166 cell growth in a cell viability assay, IC50 = 0.06619 μM. | SANGER | ||
RPMI-6666 | Growth Inhibition Assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50 = 0.06798 μM. | SANGER | ||
BC-1 | Growth Inhibition Assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50 = 0.06973 μM. | SANGER | ||
CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 0.07303 μM. | SANGER | ||
HC-1 | Growth Inhibition Assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 0.08314 μM. | SANGER | ||
JiyoyeP-2003 | Growth Inhibition Assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50 = 0.08371 μM. | SANGER | ||
RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.08572 μM. | SANGER | ||
PF-382 | Growth Inhibition Assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50 = 0.0859 μM. | SANGER | ||
G-361 | Growth Inhibition Assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 0.08815 μM. | SANGER | ||
LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 0.08833 μM. | SANGER | ||
A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 0.09169 μM. | SANGER | ||
EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 0.09558 μM. | SANGER | ||
LOUCY | Growth Inhibition Assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50 = 0.09641 μM. | SANGER | ||
HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 0.09739 μM. | SANGER | ||
MC116 | Growth Inhibition Assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50 = 0.10014 μM. | SANGER | ||
CESS | Growth Inhibition Assay | Inhibition of human CESS cell growth in a cell viability assay, IC50 = 0.1011 μM. | SANGER | ||
REH | Growth Inhibition Assay | Inhibition of human REH cell growth in a cell viability assay, IC50 = 0.10382 μM. | SANGER | ||
HCC2157 | Growth Inhibition Assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 0.10455 μM. | SANGER | ||
HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 0.10728 μM. | SANGER | ||
BL-70 | Growth Inhibition Assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50 = 0.10805 μM. | SANGER | ||
NCI-H1770 | Growth Inhibition Assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 0.10865 μM. | SANGER | ||
SK-MM-2 | Growth Inhibition Assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50 = 0.10944 μM. | SANGER | ||
MONO-MAC-6 | Growth Inhibition Assay | Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50 = 0.11372 μM. | SANGER | ||
SR | Growth Inhibition Assay | Inhibition of human SR cell growth in a cell viability assay, IC50 = 0.11387 μM. | SANGER | ||
MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 0.11446 μM. | SANGER | ||
KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 0.12924 μM. | SANGER | ||
ST486 | Growth Inhibition Assay | Inhibition of human ST486 cell growth in a cell viability assay, IC50 = 0.13527 μM. | SANGER | ||
HDLM-2 | Growth Inhibition Assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 0.13616 μM. | SANGER | ||
ARH-77 | Growth Inhibition Assay | Inhibition of human ARH-77 cell growth in a cell viability assay, IC50 = 0.1406 μM. | SANGER | ||
EB2 | Growth Inhibition Assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50 = 0.14234 μM. | SANGER | ||
CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 0.14576 μM. | SANGER | ||
HD-MY-Z | Growth Inhibition Assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50 = 0.14791 μM. | SANGER | ||
BT-474 | Growth Inhibition Assay | Inhibition of human BT-474 cell growth in a cell viability assay, IC50 = 0.15074 μM. | SANGER | ||
KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 0.16984 μM. | SANGER | ||
Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 0.1715 μM. | SANGER | ||
MC-CAR | Growth Inhibition Assay | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50 = 0.17153 μM. | SANGER | ||
MRK-nu-1 | Growth Inhibition Assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50 = 0.17751 μM. | SANGER | ||
MHH-PREB-1 | Growth Inhibition Assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 0.18242 μM. | SANGER | ||
SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 0.18514 μM. | SANGER | ||
BL-41 | Growth Inhibition Assay | Inhibition of human BL-41 cell growth in a cell viability assay, IC50 = 0.18943 μM. | SANGER | ||
CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 0.19307 μM. | SANGER | ||
NCI-H1522 | Growth Inhibition Assay | Inhibition of human NCI-H1522 cell growth in a cell viability assay, IC50 = 0.19355 μM. | SANGER | ||
CA46 | Growth Inhibition Assay | Inhibition of human CA46 cell growth in a cell viability assay, IC50 = 0.19556 μM. | SANGER | ||
L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 0.21121 μM. | SANGER | ||
NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 0.21446 μM. | SANGER | ||
GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 0.21764 μM. | SANGER | ||
OPM-2 | Growth Inhibition Assay | Inhibition of human OPM-2 cell growth in a cell viability assay, IC50 = 0.21791 μM. | SANGER | ||
U-698-M | Growth Inhibition Assay | Inhibition of human U-698-M cell growth in a cell viability assay, IC50 = 0.21915 μM. | SANGER | ||
CAL-148 | Growth Inhibition Assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50 = 0.22342 μM. | SANGER | ||
L-428 | Growth Inhibition Assay | Inhibition of human L-428 cell growth in a cell viability assay, IC50 = 0.22499 μM. | SANGER | ||
DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 0.22825 μM. | SANGER | ||
LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 0.23116 μM. | SANGER | ||
MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 0.23399 μM. | SANGER | ||
DOHH-2 | Growth Inhibition Assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50 = 0.24513 μM. | SANGER | ||
RPMI-8226 | Growth Inhibition Assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 0.24596 μM. | SANGER | ||
NCI-H2196 | Growth Inhibition Assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50 = 0.24776 μM. | SANGER | ||
COR-L279 | Growth Inhibition Assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50 = 0.25293 μM. | SANGER | ||
CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 0.25589 μM. | SANGER | ||
NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 0.26322 μM. | SANGER | ||
SUP-T1 | Growth Inhibition Assay | Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50 = 0.26516 μM. | SANGER | ||
MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 0.2687 μM. | SANGER | ||
CHP-126 | Growth Inhibition Assay | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50 = 0.26909 μM. | SANGER | ||
HCC1599 | Growth Inhibition Assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50 = 0.27841 μM. | SANGER | ||
EB-3 | Growth Inhibition Assay | Inhibition of human EB-3 cell growth in a cell viability assay, IC50 = 0.29293 μM. | SANGER | ||
WSU-NHL | Growth Inhibition Assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50 = 0.29672 μM. | SANGER | ||
COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 0.3025 μM. | SANGER | ||
LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 0.30816 μM. | SANGER | ||
TGW | Growth Inhibition Assay | Inhibition of human TGW cell growth in a cell viability assay, IC50 = 0.31095 μM. | SANGER | ||
NCI-SNU-1 | Growth Inhibition Assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 0.31106 μM. | SANGER | ||
MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 0.32291 μM. | SANGER | ||
COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 0.32838 μM. | SANGER | ||
U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 0.33314 μM. | SANGER | ||
HT | Growth Inhibition Assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 0.33482 μM. | SANGER | ||
THP-1 | Growth Inhibition Assay | Inhibition of human THP-1 cell growth in a cell viability assay, IC50 = 0.34164 μM. | SANGER | ||
HCC2218 | Growth Inhibition Assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50 = 0.3418 μM. | SANGER | ||
KARPAS-422 | Growth Inhibition Assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50 = 0.34433 μM. | SANGER | ||
EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 0.34443 μM. | SANGER | ||
TUR | Growth Inhibition Assay | Inhibition of human TUR cell growth in a cell viability assay, IC50 = 0.34453 μM. | SANGER | ||
MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 0.34596 μM. | SANGER | ||
DMS-153 | Growth Inhibition Assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50 = 0.37276 μM. | SANGER | ||
J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 0.37831 μM. | SANGER | ||
EVSA-T | Growth Inhibition Assay | Inhibition of human EVSA-T cell growth in a cell viability assay, IC50 = 0.38095 μM. | SANGER | ||
SHP-77 | Growth Inhibition Assay | Inhibition of human SHP-77 cell growth in a cell viability assay, IC50 = 0.38298 μM. | SANGER | ||
D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 0.38569 μM. | SANGER | ||
GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 0.39536 μM. | SANGER | ||
KMOE-2 | Growth Inhibition Assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 0.39664 μM. | SANGER | ||
U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 0.40452 μM. | SANGER | ||
NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 0.40703 μM. | SANGER | ||
KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 0.40876 μM. | SANGER | ||
NCI-H1882 | Growth Inhibition Assay | Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50 = 0.40912 μM. | SANGER | ||
KMS-12-PE | Growth Inhibition Assay | Inhibition of human KMS-12-PE cell growth in a cell viability assay, IC50 = 0.41877 μM. | SANGER | ||
KM-H2 | Growth Inhibition Assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 0.42374 μM. | SANGER | ||
NCI-H1417 | Growth Inhibition Assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50 = 0.43916 μM. | SANGER | ||
RPMI-8402 | Growth Inhibition Assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50 = 0.44161 μM. | SANGER | ||
EW-18 | Growth Inhibition Assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.45104 μM. | SANGER | ||
HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 0.45751 μM. | SANGER | ||
NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 0.46847 μM. | SANGER | ||
NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 0.48029 μM. | SANGER | ||
P12-ICHIKAWA | Growth Inhibition Assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 0.48862 μM. | SANGER | ||
DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 0.48893 μM. | SANGER | ||
SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 0.49478 μM. | SANGER | ||
ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 0.49906 μM. | SANGER | ||
ECC4 | Growth Inhibition Assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50 = 0.50901 μM. | SANGER | ||
LU-65 | Growth Inhibition Assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 0.52007 μM. | SANGER | ||
NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 0.54078 μM. | SANGER | ||
NCI-H187 | Growth Inhibition Assay | Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50 = 0.54464 μM. | SANGER | ||
LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 0.5472 μM. | SANGER | ||
LC4-1 | Growth Inhibition Assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50 = 0.56308 μM. | SANGER | ||
NCI-H1436 | Growth Inhibition Assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50 = 0.59043 μM. | SANGER | ||
NCI-H2171 | Growth Inhibition Assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50 = 0.62179 μM. | SANGER | ||
LB647-SCLC | Growth Inhibition Assay | Inhibition of human LB647-SCLC cell growth in a cell viability assay, IC50 = 0.62241 μM. | SANGER | ||
NCI-H2141 | Growth Inhibition Assay | Inhibition of human NCI-H2141 cell growth in a cell viability assay, IC50 = 0.63266 μM. | SANGER | ||
NCI-H1304 | Growth Inhibition Assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 0.63388 μM. | SANGER | ||
Raji | Growth Inhibition Assay | Inhibition of human Raji cell growth in a cell viability assay, IC50 = 0.66976 μM. | SANGER | ||
NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.68575 μM. | SANGER | ||
NCI-H510A | Growth Inhibition Assay | Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50 = 0.69172 μM. | SANGER | ||
COR-L88 | Growth Inhibition Assay | Inhibition of human COR-L88 cell growth in a cell viability assay, IC50 = 0.72456 μM. | SANGER | ||
K052 | Growth Inhibition Assay | Inhibition of human K052 cell growth in a cell viability assay, IC50 = 0.79127 μM. | SANGER | ||
SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 0.80231 μM. | SANGER | ||
KY821 | Growth Inhibition Assay | Inhibition of human KY821 cell growth in a cell viability assay, IC50 = 0.81743 μM. | SANGER | ||
MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 0.82406 μM. | SANGER | ||
MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 0.82745 μM. | SANGER | ||
L-540 | Growth Inhibition Assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50 = 0.84843 μM. | SANGER | ||
MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 0.86048 μM. | SANGER | ||
NCI-SNU-5 | Growth Inhibition Assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 0.94375 μM. | SANGER | ||
KARPAS-299 | Growth Inhibition Assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50 = 0.94828 μM. | SANGER | ||
NCI-H1694 | Growth Inhibition Assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50 = 0.9773 μM. | SANGER | ||
P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 0.99292 μM. | SANGER | ||
LU-165 | Growth Inhibition Assay | Inhibition of human LU-165 cell growth in a cell viability assay, IC50 = 1.05606 μM. | SANGER | ||
NB1 | Growth Inhibition Assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50 = 1.11241 μM. | SANGER | ||
UACC-812 | Growth Inhibition Assay | Inhibition of human UACC-812 cell growth in a cell viability assay, IC50 = 1.1488 μM. | SANGER | ||
RL | Growth Inhibition Assay | Inhibition of human RL cell growth in a cell viability assay, IC50 = 1.16282 μM. | SANGER | ||
NCI-H69 | Growth Inhibition Assay | Inhibition of human NCI-H69 cell growth in a cell viability assay, IC50 = 1.19391 μM. | SANGER | ||
SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 1.23671 μM. | SANGER | ||
NCI-H1155 | Growth Inhibition Assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 1.27588 μM. | SANGER | ||
NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 1.44028 μM. | SANGER | ||
MHH-CALL-2 | Growth Inhibition Assay | Inhibition of human MHH-CALL-2 cell growth in a cell viability assay, IC50 = 1.48514 μM. | SANGER | ||
SCLC-21H | Growth Inhibition Assay | Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50 = 1.67837 μM. | SANGER | ||
LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 1.71089 μM. | SANGER | ||
CPC-N | Growth Inhibition Assay | Inhibition of human CPC-N cell growth in a cell viability assay, IC50 = 1.76764 μM. | SANGER | ||
SCC-3 | Growth Inhibition Assay | Inhibition of human SCC-3 cell growth in a cell viability assay, IC50 = 2.04311 μM. | SANGER | ||
NCI-H446 | Growth Inhibition Assay | Inhibition of human NCI-H446 cell growth in a cell viability assay, IC50 = 2.05293 μM. | SANGER | ||
RH-1 | Growth Inhibition Assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 2.13933 μM. | SANGER | ||
NCI-H345 | Growth Inhibition Assay | Inhibition of human NCI-H345 cell growth in a cell viability assay, IC50 = 2.14996 μM. | SANGER | ||
A253 | Growth Inhibition Assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 2.25377 μM. | SANGER | ||
DMS-79 | Growth Inhibition Assay | Inhibition of human DMS-79 cell growth in a cell viability assay, IC50 = 2.36386 μM. | SANGER | ||
SK-N-FI | Growth Inhibition Assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 2.50034 μM. | SANGER | ||
SK-MEL-1 | Growth Inhibition Assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 2.61066 μM. | SANGER | ||
HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 2.69128 μM. | SANGER | ||
SIMA | Growth Inhibition Assay | Inhibition of human SIMA cell growth in a cell viability assay, IC50 = 2.72143 μM. | SANGER | ||
SU-DHL-1 | Growth Inhibition Assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50 = 2.90246 μM. | SANGER | ||
P31-FUJ | Growth Inhibition Assay | Inhibition of human P31-FUJ cell growth in a cell viability assay, IC50 = 3.01209 μM. | SANGER | ||
A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 3.23245 μM. | SANGER | ||
RPMI-8866 | Growth Inhibition Assay | Inhibition of human RPMI-8866 cell growth in a cell viability assay, IC50 = 3.58797 μM. | SANGER | ||
NCI-H209 | Growth Inhibition Assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 3.59247 μM. | SANGER | ||
JVM-2 | Growth Inhibition Assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 3.62244 μM. | SANGER | ||
LP-1 | Growth Inhibition Assay | Inhibition of human LP-1 cell growth in a cell viability assay, IC50 = 3.79042 μM. | SANGER | ||
IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 3.91611 μM. | SANGER | ||
TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 3.99619 μM. | SANGER | ||
NCI-H1618 | Growth Inhibition Assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50 = 4.17788 μM. | SANGER | ||
COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 4.51462 μM. | SANGER | ||
KU-19-19 | Growth Inhibition Assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 4.56729 μM. | SANGER | ||
HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 5.75167 μM. | SANGER | ||
DG-75 | Growth Inhibition Assay | Inhibition of human DG-75 cell growth in a cell viability assay, IC50 = 6.18885 μM. | SANGER | ||
CCF-STTG1 | Growth Inhibition Assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50 = 6.74902 μM. | SANGER | ||
SBC-1 | Growth Inhibition Assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 6.88808 μM. | SANGER | ||
CAL-85-1 | Growth Inhibition Assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 7.45587 μM. | SANGER | ||
BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 7.56085 μM. | SANGER | ||
YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 7.74286 μM. | SANGER | ||
HCC1806 | Growth Inhibition Assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 8.04507 μM. | SANGER | ||
SK-MEL-28 | Growth Inhibition Assay | Inhibition of human SK-MEL-28 cell growth in a cell viability assay, IC50 = 8.42441 μM. | SANGER | ||
Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 8.62748 μM. | SANGER | ||
NCI-H889 | Growth Inhibition Assay | Inhibition of human NCI-H889 cell growth in a cell viability assay, IC50 = 9.42457 μM. | SANGER | ||
HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 9.4754 μM. | SANGER | ||
H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 9.59864 μM. | SANGER | ||
NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 9.87581 μM. | SANGER | ||
M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 10.5224 μM. | SANGER | ||
OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 11.4748 μM. | SANGER | ||
HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 11.4776 μM. | SANGER | ||
RT4 | Growth Inhibition Assay | Inhibition of human RT4 cell growth in a cell viability assay, IC50 = 11.6532 μM. | SANGER | ||
SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 12.004 μM. | SANGER | ||
BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 12.0436 μM. | SANGER | ||
HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 12.7585 μM. | SANGER | ||
KU812 | Growth Inhibition Assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 13.9562 μM. | SANGER | ||
JAR | Growth Inhibition Assay | Inhibition of human JAR cell growth in a cell viability assay, IC50 = 14.113 μM. | SANGER | ||
NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 14.287 μM. | SANGER | ||
HuO9 | Growth Inhibition Assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 14.4446 μM. | SANGER | ||
U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 14.5013 μM. | SANGER | ||
SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 14.942 μM. | SANGER | ||
ES5 | Growth Inhibition Assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 15.3528 μM. | SANGER | ||
NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 15.4452 μM. | SANGER | ||
COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 15.6978 μM. | SANGER | ||
NCI-H524 | Growth Inhibition Assay | Inhibition of human NCI-H524 cell growth in a cell viability assay, IC50 = 15.751 μM. | SANGER | ||
HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 16.1017 μM. | SANGER | ||
GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 16.5577 μM. | SANGER | ||
LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 16.8228 μM. | SANGER | ||
HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 17.176 μM. | SANGER | ||
SW837 | Growth Inhibition Assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 17.3011 μM. | SANGER | ||
NCI-N87 | Growth Inhibition Assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50 = 17.5302 μM. | SANGER | ||
BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 17.7386 μM. | SANGER | ||
Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 17.8382 μM. | SANGER | ||
MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 18.2784 μM. | SANGER | ||
NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 18.3793 μM. | SANGER | ||
Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 19.7889 μM. | SANGER | ||
SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 19.9447 μM. | SANGER | ||
Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 20.3327 μM. | SANGER | ||
A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 20.4092 μM. | SANGER | ||
COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 20.9232 μM. | SANGER | ||
OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 21.2508 μM. | SANGER | ||
K-562 | Growth Inhibition Assay | Inhibition of human K-562 cell growth in a cell viability assay, IC50 = 21.9049 μM. | SANGER | ||
IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 22.3771 μM. | SANGER | ||
SK-LMS-1 | Growth Inhibition Assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 22.4057 μM. | SANGER | ||
CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 23.0872 μM. | SANGER | ||
NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 24.1303 μM. | SANGER | ||
GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 24.4376 μM. | SANGER | ||
NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 24.6005 μM. | SANGER | ||
MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 24.6906 μM. | SANGER | ||
SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 24.9296 μM. | SANGER | ||
MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 26.4465 μM. | SANGER | ||
HCC1954 | Growth Inhibition Assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 26.4502 μM. | SANGER | ||
SAS | Growth Inhibition Assay | Inhibition of human SAS cell growth in a cell viability assay, IC50 = 26.4732 μM. | SANGER | ||
SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 26.5693 μM. | SANGER | ||
MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 26.7093 μM. | SANGER | ||
T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 26.7743 μM. | SANGER | ||
HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 26.9389 μM. | SANGER | ||
DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 27.0723 μM. | SANGER | ||
SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 28.0766 μM. | SANGER | ||
HCC1143 | Growth Inhibition Assay | Inhibition of human HCC1143 cell growth in a cell viability assay, IC50 = 28.2552 μM. | SANGER | ||
JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 28.4578 μM. | SANGER | ||
SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 28.6049 μM. | SANGER | ||
NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 28.8033 μM. | SANGER | ||
Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 29.1197 μM. | SANGER | ||
HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 29.4423 μM. | SANGER | ||
EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 29.5269 μM. | SANGER | ||
639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 29.8546 μM. | SANGER | ||
IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 30.0191 μM. | SANGER | ||
LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 30.351 μM. | SANGER | ||
D-502MG | Growth Inhibition Assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 30.3725 μM. | SANGER | ||
AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 31.4329 μM. | SANGER | ||
RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 31.4464 μM. | SANGER | ||
GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 31.7096 μM. | SANGER | ||
BB30-HNC | Growth Inhibition Assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 32.5217 μM. | SANGER | ||
HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 32.7065 μM. | SANGER | ||
NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 33.3495 μM. | SANGER | ||
D-542MG | Growth Inhibition Assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 33.3722 μM. | SANGER | ||
NCI-H727 | Growth Inhibition Assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 33.4114 μM. | SANGER | ||
NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 33.5236 μM. | SANGER | ||
KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 33.6298 μM. | SANGER | ||
SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 33.7643 μM. | SANGER | ||
MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 33.8103 μM. | SANGER | ||
NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 34.326 μM. | SANGER | ||
LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 34.8526 μM. | SANGER | ||
HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 35.022 μM. | SANGER | ||
SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 35.2684 μM. | SANGER | ||
IM-9 | Growth Inhibition Assay | Inhibition of human IM-9 cell growth in a cell viability assay, IC50 = 35.5165 μM. | SANGER | ||
KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 35.6521 μM. | SANGER | ||
HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 35.6756 μM. | SANGER | ||
CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 35.7968 μM. | SANGER | ||
22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 35.8423 μM. | SANGER | ||
SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 36.2464 μM. | SANGER | ||
COLO-205 | Growth Inhibition Assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50 = 37.2589 μM. | SANGER | ||
MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 37.3918 μM. | SANGER | ||
ECC12 | Growth Inhibition Assay | Inhibition of human ECC12 cell growth in a cell viability assay, IC50 = 37.7142 μM. | SANGER | ||
CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 37.7221 μM. | SANGER | ||
KNS-42 | Growth Inhibition Assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50 = 37.8215 μM. | SANGER | ||
U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 37.827 μM. | SANGER | ||
EFE-184 | Growth Inhibition Assay | Inhibition of human EFE-184 cell growth in a cell viability assay, IC50 = 37.8863 μM. | SANGER | ||
TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 38.3341 μM. | SANGER | ||
TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 39.2614 μM. | SANGER | ||
SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 39.5577 μM. | SANGER | ||
NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 39.5618 μM. | SANGER | ||
NCI-H748 | Growth Inhibition Assay | Inhibition of human NCI-H748 cell growth in a cell viability assay, IC50 = 39.6102 μM. | SANGER | ||
HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 39.8492 μM. | SANGER | ||
GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 40.2935 μM. | SANGER | ||
LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 40.6473 μM. | SANGER | ||
TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 40.7998 μM. | SANGER | ||
NCI-H1993 | Growth Inhibition Assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 41.1086 μM. | SANGER | ||
769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 41.226 μM. | SANGER | ||
NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 41.3099 μM. | SANGER | ||
NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 41.353 μM. | SANGER | ||
NCI-H82 | Growth Inhibition Assay | Inhibition of human NCI-H82 cell growth in a cell viability assay, IC50 = 41.4039 μM. | SANGER | ||
SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 41.6769 μM. | SANGER | ||
NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 41.9392 μM. | SANGER | ||
A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 42.1236 μM. | SANGER | ||
SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 42.3151 μM. | SANGER | ||
EKVX | Growth Inhibition Assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 42.3726 μM. | SANGER | ||
A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 42.8624 μM. | SANGER | ||
OMC-1 | Growth Inhibition Assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50 = 42.9399 μM. | SANGER | ||
PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 43.157 μM. | SANGER | ||
NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 43.3223 μM. | SANGER | ||
HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 43.7863 μM. | SANGER | ||
BV-173 | Growth Inhibition Assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 43.7946 μM. | SANGER | ||
LS-1034 | Growth Inhibition Assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 43.9899 μM. | SANGER | ||
NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 44.0773 μM. | SANGER | ||
IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 44.2633 μM. | SANGER | ||
8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 44.31 μM. | SANGER | ||
IMR-5 | Growth Inhibition Assay | Inhibition of human IMR-5 cell growth in a cell viability assay, IC50 = 44.5743 μM. | SANGER | ||
TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 44.8539 μM. | SANGER | ||
MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 45.0112 μM. | SANGER | ||
RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 45.4472 μM. | SANGER | ||
SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 45.5616 μM. | SANGER | ||
SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 45.5626 μM. | SANGER | ||
CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 45.6635 μM. | SANGER | ||
LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 45.6839 μM. | SANGER | ||
NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 45.7286 μM. | SANGER | ||
K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 46.029 μM. | SANGER | ||
LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 46.4256 μM. | SANGER | ||
MES-SA | Growth Inhibition Assay | Inhibition of human MES-SA cell growth in a cell viability assay, IC50 = 46.5121 μM. | SANGER | ||
UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 46.5175 μM. | SANGER | ||
NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 46.8809 μM. | SANGER | ||
TE-15 | Growth Inhibition Assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50 = 46.8909 μM. | SANGER | ||
SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 47.3821 μM. | SANGER | ||
NCI-H322M | Growth Inhibition Assay | Inhibition of human NCI-H322M cell growth in a cell viability assay, IC50 = 47.6561 μM. | SANGER | ||
SK-OV-3 | Growth Inhibition Assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 47.7452 μM. | SANGER | ||
PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 47.9641 μM. | SANGER | ||
786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 48.073 μM. | SANGER | ||
NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 48.1255 μM. | SANGER | ||
D-336MG | Growth Inhibition Assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50 = 48.4845 μM. | SANGER | ||
SNG-M | Growth Inhibition Assay | Inhibition of human SNG-M cell growth in a cell viability assay, IC50 = 48.6701 μM. | SANGER | ||
SK-CO-1 | Growth Inhibition Assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50 = 49.0025 μM. | SANGER | ||
CAL-27 | Growth Inhibition Assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 49.5334 μM. | SANGER | ||
8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 49.5364 μM. | SANGER | ||
MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 49.5865 μM. | SANGER | ||
T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 49.7007 μM. | SANGER | ||
YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 49.9412 μM. | SANGER | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | A-769662是一種有效的,可逆的AMPK激活劑,在無細胞試驗中EC50為0.8 μM,對GPPase/FBPase活性幾乎沒有作用。 | ||||
---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | A-769662部分刺激純化的大鼠肝臟AMPK,EC50 為0.8 μM。A-769662以劑量響應的方式激活從多種組織和物種純化得到的AMPK,伴隨不同的EC50s。A-769662的EC50s,使用從大鼠心臟,大鼠肌肉,或人胚腎細胞(HEKs)部分純化的AMPK測定,結(jié)果分別為2.2 mM,1.9 mM,或1.1 mM。原代大鼠肝細胞用A-769662處理4小時劑量依賴性增加ACC磷酸化,其與脂肪酸合成的抑制相關(guān),IC50為3.2 μM。A-769662也會抑制小鼠肝細胞中脂肪酸合成,IC50為3.6 μM。[1] A-769662通過變構(gòu)調(diào)節(jié)和抑制AMPK在Thr-172上的去磷酸化作用激活AMPK,類似于AMP的作用。[2] A-769662通過與AMPK無關(guān)的作用機制抑制蛋白酶體功能。 A-769662影響純化26S蛋白酶體的體外活性,但是不影響純化20S蛋白酶體的體外活性。A-769662對MEF細胞具有毒性作用。[3]一項最近的研究表明,A-769662抑制細胞增殖和DNA合成。[4] |
|||
---|---|---|---|---|
激酶實驗 | 96-孔 AMPK 試驗 | |||
AMPK活性通過監(jiān)測SAMS多肽底物(標準試驗中為20 μM,附加試驗中為100 μM)磷酸化根據(jù)前述方案(Anderson et al., 2004)測量。為測定 A-769662誘導的AMPK活化是否可逆,AMP或A-769662與大鼠肝臟AMPK在20倍標準試驗濃度下預培養(yǎng)10分鐘,然后稀釋并測量AMPK活性。 | ||||
細胞實驗 | 細胞系 | MEF細胞 | ||
濃度 | 300 μM | |||
孵育時間 | 24小時 | |||
方法 | A-769662處理或未處理的MEF細胞的細胞活性如下進行測定:細胞通過胰蛋白酶化采集,并與0.5 mg/mL RNase 和50 μg/mL碘化丙啶在室溫下黑暗中進行培育;細胞活性通過流式細胞術(shù)使用FACScanto流式細胞分析儀分析,激發(fā)激光波長為488 nm,碘化丙啶熒光檢測波長為600 nm。為測定細胞周期各階段的細胞比例,細胞通過胰蛋白酶化采集,通過離心收集,用PBS洗滌,并在80%乙醇中于-20°C固定過夜。隨后,將這些固定的細胞離心以除去固定劑,并于黑暗中,室溫下,在包含0.5 mg/mL RNase 和50 μg/mL碘化丙啶的PBS中培養(yǎng)20分鐘。流式細胞術(shù)分析如上進行。G1,S,和G2期的細胞比例使用MODFIT程序測定。細胞培養(yǎng)照片在指示時間使用結(jié)合具有20倍物鏡的倒置顯微鏡的相機拍攝。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | pCofilin / Cofilin / detyrosinated alpha tubulin / acetylated alpha tubulin p-AMPK / AMPK / p-S6K / S6K / p-ACC | 26431377 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | A-769662對正常Sprague Dawley大鼠的短期治療降低肝臟丙二酰CoA水平,和換氣比值,VCO2/VO2,表明整體脂肪酸氧化比率增加。A-769662(30 mg/kg, b.i.d.)治療ob/ob小鼠,減少PEPCK,G6Pase,和FAS的肝臟表達,降低40%血漿葡萄糖,減少體重增加,并顯著降低血漿和肝臟甘油三酯水平。[1] |
|
---|---|---|
動物實驗 | Animal Models | Sprague Dawley大鼠 |
Dosages | 30 mg/kg | |
Administration | 腹腔注射給藥 |
分子量 | 360.39 | 分子式 | C20H12N2O3S |
CAS號 | 844499-71-4 | SDF | Download A-769662 SDF |
Smiles | C1=CC=C(C(=C1)C2=CC=C(C=C2)C3=CSC4=C3C(=C(C(=O)N4)C#N)O)O | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 72 mg/mL ( (199.78 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項